Cancer patients who need cell therapy can now get their treatment in India at about one-tenth the cost in the US. Wondering how? Well, Indian start-ups and pharmaceutical companies will now offer cell therapy treatment at cheaper rates.Also read – Popular Assamese actor Kishore Das dies of cancer at age 30, last photo from hospital goes viral
Reported by Business standard Said, “Supported by Immunil Therapeutics, Kiran Mazumdar Shaw, Chairperson of Biocon and Siddharth Mukherjee, US Oncologist; Dr. Reddy’s Laboratories and Chinese firm Shenzhen Prigen Biopharma; And IIT Bombay Spin-Off, Immunect, is one of the companies working to bring CAR T-cell therapy for cancer in India, especially blood cancer, in the next two years. ” Also read – 5 General health problems men should be aware of
In the U.S., treatment of blood cell cancer-leukemia by CAR T-cell therapy costs $ 800,000- $ 900,000 (approximately Rs. 6-7 crores). Also read – Can cancer magically disappear? Incredible results come as a surprise to doctors in the new drug trial
CAR T-cells (chimeric antigen receptor T-cells) produce synthetic T-cell receptors. The immune system also helps fight infections, abnormal cells and cancer cells. “Cellular immunotherapy strategies use the patient’s immune cells, which are then genetically altered outside the body and reintroduced,” the report said. The results start appearing in a week and last for years. ”
According to reports, more than 1 million new cases of cancer are reported in India every year. Unfortunately, mortality is higher in India. But the good news is that things will change for the better now.
Arun Anand, director and chief operating officer of Immune Therapeutics, told Business Standard that CAR T-cell therapy for cancers such as leukemia has the potential to reduce three years of conventional treatment (using oral drugs, chemotherapy, bone marrow transplants, etc.). Three weeks.
How much will the treatment cost?
Anand told the publication, “This therapy costs US આશ 450,000. However, with before and after patient care, the accumulated costs in the U.S. range from US 800 800,000 to US 900 900,000. He says he wants to offer it in India at one-tenth of US spending.
“India can be a medical tourism hub,” Anand said.
